Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 10.

Santos, J R; Cozzi-Lepri, A; Phillips, A; De Wit, S; Pedersen, C; Reiss, P; Blaxhult, A; Lazzarin, A; Sluzhynska, M; Orkin, C; Duvivier, C; Bogner, J; Gargalianos-Kakolyris, P; Schmid, P; Hassoun, G; Khromova, I; Beniowski, M; Hadziosmanovic, V; Sedlacek, D; Paredes, R; Lundgren, J D; EuroSIDA study group (2018). Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. HIV Medicine, 19(5):324-338.

Cozzi-Lepri, A; Zangerle, R; Machala, L; Zilmer, K; Ristola, M; Pradier, C; Kirk, O; Sambatakou, H; Fätkenheuer, G; Yust, I; Schmid, P; Gottfredsson, M; Khromova, I; Jilich, D; Flisiak, R; Smidt, J; Rozentale, B; Radoi, R; Losso, M H; Lundgren, J D; Mocroft, A; EuroSIDA Study Group (2018). Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. HIV Medicine, 19(2):102-117.

Noguera-Julian, M; Cozzi-Lepri, A; Di Giallonardo, F; Schuurman, R; Däumer, M; Aitken, S; Ceccherini-Silberstein, F; D'Arminio Monforte, A; Geretti, A M; Booth, C L; Kaiser, R; Michalik, C; Jansen, K; Masquelier, B; Bellecave, P; Kouyos, R D; Castro, E; Furrer, H; Schultze, A; Günthard, H F; Brun-Vezinet, F; Metzner, K J; Paredes, R (2016). Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants. Clinical Microbiology and Infection, 22(2):191-200.

Vingerhoets, J; Calvez, V; Flandre, P; Marcelin, A G; Ceccherini-Silberstein, F; Perno, C F; Mercedes Santoro, M; Bateson, R; Nelson, M; Cozzi-Lepri, A; Grarup, J; Lundgren, J; Incardona, F; Kaiser, R; Sonnerborg, A; Clotet, B; Paredes, R; Günthard, Hf; Ledergerber, B; Hoogstoel, A; Nijs, S; Tambuyzer, L; Lavreys, L; Opsomer, M; Etravirine Cohort Study Group (2015). Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data. HIV Medicine, 16(5):297-306.

Cozzi-Lepri, A; Paredes, R; Phillips, A N; Clotet, B; Kjaer, J; Von Wyl, V; Kronborg, G; Castagna, A; Bogner, J R; Lundgren, J D (2012). The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI. HIV Medicine, 13(1):62-72.

Wittkop, L; Günthard, H F; de Wolf, F; Dunn, D; Cozzi-Lepri, A; de Luca, A; Kücherer, C; Obel, N; von Wyl, V; Masquelier, B; Stephan, C; Torti, C; Antinori, A; García, F; Judd, A; Porter, K; Thiébaut, R; Castro, H; van Sighem, A I; Colin, C; Kjaer, J; Lundgren, J D; Paredes, R; Pozniak, A; Clotet, B; Phillips, A; Pillay, D; Chêne, G (2011). Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infectious Diseases, 11(5):363-371.

Lodwick, R K; Sabin, C A; Porter, K; Ledergerber, B; van Sighem, A; Cozzi-Lepri, A; Khaykin, P; Mocroft, A; Jacobson, L; De Wit, S; Obel, N; Castagna, A; Wasmuth, J C; Gill, J; Klein, M B; Gange, S; Riera, M; Mussini, C; Gutiérrez, F; Touloumi, G; Carrieri, P; Guest, J L; Brockmeyer, N H; Phillips, A N (2010). Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet, 376(9738):340-345.

Lodwick, R; Costagliola, D; Reiss, P; Torti, C; Teira, R; Dorrucci, M; Ledergerber, B; Mocroft, A; Podzamczer, D; Cozzi-Lepri, A; Obel, N; Masquelier, B; Staszewski, S; García, F; De Wit, S; Castagna, A; Antinori, A; Judd, A; Ghosn, J; Touloumi, G; Mussini, C; Duval, X; Ramos, J; Meyer, L; Warsawski, J; Thorne, C; Masip, J; Pérez-Hoyos, S; Pillay, D; van Sighem, A; Lo Caputo, S; Günthard, H; Paredes, R; De Luca, A; Paraskevis, D; Fabre-Colin, C; Kjaer, J; Chêne, G; Lundgren, J D; Phillips, A N (2010). Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Archives of Internal Medicine, 170(5):410-419.

Fellay, J; Ge, D; Shianna, K V; Colombo, S; Ledergerber, B; Cirulli, E T; Urban, T J; Zhang, K; Gumbs, C E; Smith, J P; Castagna, A; Cozzi-Lepri, A; De Luca, A; Easterbrook, P; Günthard, H F; Mallal, S; Mussini, C; Dalmau, J; Martinez-Picado, J; Miro, J M; Obel, N; Wolinsky, S M; Martinson, J J; Detels, R; Margolick, J B; Jacobson, L P; Descombes, P; Antonarakis, S E; Beckmann, J S; O'Brien, S J; Letvin, N L; McMichael, A J; Haynes, B F; Carrington, M; Feng, S; Telenti, A; Goldstein, D B (2009). Common genetic variation and the control of HIV-1 in humans. PLoS Genetics, 5(12):e1000791.

Gupta, R K; Hill, A; Sawyer, A W; Cozzi-Lepri, A; von Wyl, V; Yerly, S; Lima, V D; Günthard, H F; Gilks, C; Pillay, D (2009). Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infectious Diseases, 9(7):409-447.

This list was generated on Mon Dec 10 09:30:30 2018 CET.